Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer

NCT01495676 is registered in ClinicalTrials.gov with Institut du Cancer de Montpellier - Val d'Aurelle as lead sponsor.

NCT NCT01495676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01495676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer
Lead sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Phase
Not applicable
Overall status
Terminated
Start date
July 6, 2011
Completion date
December 7, 2024
Enrollment
69 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

infiltrating bladder urothelial carcinoma